Editing PHKG Business Opportunities (section)

=== Verdict ===

'''The problem is real, but the opportunity is harder and narrower than it first appears.'''

* Norway already has Kjernejournal and PLL — the product is an AI summarisation layer on top, not first-ever cross-institutional access.
* The defensible niche may be narrower than "GP diagnostic overview": something like '''"structured ontology-backed summary for complex multimorbidity patients where omission risk is verifiable against the underlying PHKG"''' — leveraging the actual differentiator (PHKG structure) rather than competing on generic summarisation.
* '''Gating item is regulatory clearance and a published clinical safety evaluation''', not just data flow. Budget for a prospective clinical study, not just integration work.
* Epic's own summarisation tool, bundled with Helseplattformen, is the direct competitor. Stamen must be provably better on accuracy/omission rates, not just different on architecture.
* Year 2-3 timing is plausible but depends on completing clinical safety validation. Not before.